EQT agreed to acquire Aldevron, the global supplier of plasmid DNA used in cell and gene therapies from TA Associates. Financial terms were not disclosed. EQT will help advance Aldevron’s R&D and innovation efforts as the company continue to support the rapidly growing field of genetic medicine by providing critical input for the development of new life-saving therapies. "EQT shares our strong values and commitment to excellence and we believe their significant healthcare experience, global presence and industrial network make them an ideal partner as we continue our growth journey,” Michael Chambers, Aldevron Co-Founder and CEO.